9/ Okay, but seriously, there are many times I think of something to say online that sounds humorous in the moment, but on deeper thought I realize could come off as hurtful or mean. Sarcasm can be on of the easiest ways to trick yourself into assuming it is more valid to express
10/ ... Obviously, this is very much contextual, but I'd offer it's usually well worth the second, third, or tenth thought. If you can easily see how someone would be offended by a sarcastic remark, it might be worth finding a better way to say it -- or just not saying it at all.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
One thing that still surprises me is when I'm tweeting or retweeting opinion, articles, etc that are generally pro #LDL#Cholesterol-lowering or LDL-as-problematic (such as recently) I get some pushback...
2/ If you've followed me a long time, you should know this is something I'm proactive about doing -- in fact, I'm more active at doing it now than ever.
If you've only heard the ⬆️LDL isn't-so-bad case, please hear out the mainstream case on how ⬆️LDL *is* bad... #NoEchoChambers
3/ If you somehow hadn't already heard, I literally spearheaded a crowdfunding campaign for an IRB-approved study with longitudinal CCTAs to track plaque development
Why? Because we don't know what the risk levels are for this context. If we did, there'd be no need for the study
1/ Yes, will comment on it in time as I have some follow up questions and comments -- but for the moment, I want to reemphasize how much I appreciate @deirdre_tobias publishing the baseline charts, making the code available, and overall devoting her time to this project...
2/ Seeing this progress and unfold over a matter of weeks is fantastic. I'm used to either getting a "sneak preview" of what an analysis might show with a given dataset or be told it will require full publication (many months and dollars down the road) in order to be public...
3/ In other words, I wish we could get this kind of turnaround and transparency on every major dataset. @deirdre_tobias has effectively done something I've been asking after for years -- and she did so at no cost.
That's worth its own distinction and one I certainly laud.
2/ Recently I was much more focused on fasting (see ) and lipoprotein lipase (LPL) dynamics (see )
3/ And indeed, the regulatory strings behind LPL up and down regulation is a much bigger part of the story with regard to VLDL turnover -- and thus potential resulting effects on LDL-C, HDL-C, and Triglycerides (TG).
1/ If you want to hear a great discussion on the #LMHRstudy from my colleague,@DrNadolsky (who is most definitely pro-#LDL#Cholesterol lowering), I highly recommend this podcast that just dropped via @Plant_proof.
2/ Firstly, this may be the most I've heard myself talked about in a podcast I wasn't in (😂 weird, but understandable given the context).
But while certainly critical in many respects, I felt both @DrNadolsky and @Plant_proof provided a lot of good context...
3/ @DrNadolsky bring up my oft-repeated phrase, "cautiously optimistic" [in the context of higher LDL/ApoB as a seemingly resulting from metabolic fat-adaption]
Worth repeating that mine is a hypothesis and should be treated as such, hence the "cautious" part of the phrase...
1/ I want to take a moment to have a back-and-forth exchange with @MichaelMindrum in a thread, and I’m just gonna keep it to us (Tweet setting) I’m confident we can keep it productive. 👍
First, I think we should get on the same page with where I’m coming from..
2/ I’m not just interested in high LDL for LMHRs. I’m interested in whether it’s meaningful to distinguish high LDL from what appears to be lipid metabolic dysregulation versus high LDL in the context of metabolic fat adaptation.
3/ Much of those following this account know this already from following my work, but often critics do not.
That’s why I’d love to specificity talk to a critic I like, such as yourself, and really unpack this so we can better narrow down where the real disagreements are.